Market Research Future has added a report titled “Narcolepsy Market Research Report -
Forecast to 2023” to its offering. The report provides an in-depth analysis of regional data
and an accurate projection of the market size and share of the Top 10 market players
across the globe.
Global Narcolepsy Market is expected to grow at an approximate CAGR of 8.2%
during the forecast period.
Market Scenario:
Narcolepsy is a medical condition which is characterized by overwhelming daytime
drowsiness and sudden attacks of sleep. Sometimes, this chronic sleep disorder can lead to
a sudden loss of muscle tone (cataplexy), leading to weakness and loss of muscle control.
Sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep & insomnia, besides
others are some of the most common symptoms of the disease. Increasing prevalence of
narcolepsy and growing obese population are the major drivers of market growth during the
forecast period. According to the Sleep Science journal in 2017, it was estimated that
approximately 1 in every 2,000 people across the worldwide lives with narcolepsy.
Moreover, from 2014-2015, the Australian Institute of Health and Welfare stated that
approximately two-thirds, i.e., 63% of the Australian population which aged 18 years or
more was estimated to be overweight or obese. Additionally, increasing demands for
effective treatment of the disease followed by increasing research and development boost
the market growth. However, lack of awareness and low per capita healthcare expenditure
within the regional boundaries of middle and low-income countries is estimated to restrain
the global narcolepsy market during the forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5701
Key players in global narcolepsy market:
Jazz Pharmaceuticals plc (Republic of Ireland), BIOPROJET (Paris), Arena Pharmaceuticals,
Inc. (U.S.), Graymark Healthcare, Inc. (U.S.), Mylan N.V. (U.S., Teva Pharmaceutical
Industries Ltd. (Israel), Novartis AG (Switzerland), Shire (Republic of Ireland), Shionogi Inc.
(U.S.), Ligand Pharmaceuticals, Inc. (U.S.), and others
Segmentation:
Global Narcolepsy Market is segmented on the basis of type, diagnosis, treatment, and end
user.
On the basis of the type, the market is segmented into type 1 narcolepsy, type 2
narcolepsy, and others.
On the basis of the diagnosis, the market is categorized into polysomnogram, multiple sleep
latency test, others. On the basis of the treatment, the market is segmented into
stimulants, antidepressants, sodium oxybate, and others. The stimulants segment is sub-
segmented into modafinil, armodafinil, and others. The antidepressants segment is sub-
segmented into tricyclics, selective serotonin and noradrenergic reuptake inhibitors, and
others. The tricyclics segment is further segmented into imipramine, desipramine,
clomipramine, and others. The selective serotonin and noradrenergic reuptake inhibitors
segment are sub-segmented into venlafaxine, fluoxetine, and others. On the basis of the
end users, the market is segmented into hospitals, clinics, retail pharmacies, and others.
Regional Analysis:
America dominates the global narcolepsy market owing to a well-developed healthcare
sector, high healthcare expenditure and a huge patient population. According to the
National Institute of Neurological Disorders and Stroke in 2018, it is estimated that
approximately 135,000 to 200,000 people in the United States are living with narcolepsy.
Moreover, the presence of developed economies like U.S. and Canada and global players
such as Mylan N.V., Ligand Pharmaceuticals, Inc., and others within the regional boundaries
of the Americas fuels the market growth.
Europe is the second largest market for narcolepsy and is followed by Asia Pacific owing to
the availability of funds for research, huge patient population, growing number of obese,
and presence of developed economies like France, Italy, and Germany within the region. In